GE Healthcare CEO Succession: John Flannery In, John Dineen Moves On
This article was originally published in The Gray Sheet
Executive Summary
The lead GE business development executive John Flannery is taking over the top spot of the firm’s health care business, replacing John Dineen, who is leaving GE after seven years running Healthcare and 28 years at the company.
You may also be interested in...
Medtech Innovation From An Industrial Perspective: An Interview With GE Healthcare’s John Dineen
Because the GE brand is so ubiquitous, visible on everything from household appliances to airplane engines, it’s easy to assume a familiarity with GE and, in particular, with what its health care business is all about. But this interview with John Dineen, President and CEO of GE Healthcare and GE Medical Systems Information Technologies Inc. makes clear that GE’s world view is anything but familiar and stands in striking contrast to that of most other medical technology companies.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.